|
|
|
| Recent Progress in Drug Development against COVID-19 |
XU Ye-chun,LIU Hong,LI Jian-feng,SHEN Jing-shan,JIANG Hua-liang( ) |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China |
|
|
|
Abstract The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses tremendous threats to public health and urgently needs an effective cure. The progress in drug repurposing, therapeutic antibody and small molecule development, and traditional Chinese medicine for the treatment of COVID-19 in the early state of the outbreak were focused. A number of drugs have been revealed to inhibit the replication of SARS-CoV-2 by drug repurposing, which includes remdesivir, favipiravir, chloroquine, and hydroxychloroquine. Remedsivir is the first drug approved by the FDA for the treatment of COVID-19 in USA. As for the development of innovative drug, a major effort has been directed to the discovery of therapeutic antibodies targeting spike protein and inhibitors of 3C-like protease as well as RNA-dependent RNA polymerase of SARS-CoV-2. In addition, traditional Chinese medicine has played an important role in the prevention and treatment of COVID-19. Jinhua Qinggan granule, Lianhua Qingwen capsule, Xuebijing injection, Shuanghuanglian oral liquid, Qingfei Baidu decoction, Huashi Baidu prescription, and Xuanfei Baidu prescription have entered clinical trials for the treatment of COVID-19.
|
|
Received: 06 May 2021
Published: 06 July 2021
|
|
|
|
Corresponding Authors:
Hua-liang JIANG
E-mail: hljiang@simm.ac.cn
|
|
|
| [1] |
中华人民共和国国务院新闻办公室. 抗击新冠肺炎疫情的中国行动. 北京: 人民出版社, 2020.
|
|
|
| [1] |
The State Council Information Office of the People’s Republice of China. Fighting COVID-19 China in action. Beijing: People’s Publishing House, 2020.
|
|
|
| [2] |
Saha R P, Sharma A R, Singh M K, et al. Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19. Frontiers in Pharmacology, 2020, 11:1258.
doi: 10.3389/fphar.2020.01258
|
|
|
| [3] |
Yu F, Xiang R, Deng X Q, et al. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduction and Targeted Therapy, 2020, 5(1):212.
doi: 10.1038/s41392-020-00318-0
|
|
|
| [4] |
Wang M L, Cao R Y, Zhang L K, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 2020, 30:269-271.
doi: 10.1038/s41422-020-0282-0
|
|
|
| [5] |
Malin J J, Suárez I, Priesner V, et al. Remdesivir against COVID-19 and other viral diseases. Clinical Microbiology Reviews, 2020, 34(1):e00162-20.
|
|
|
| [6] |
Wang Y M, Zhang D Y, Du G H, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020, 395(10236):1569-1578.
doi: 10.1016/S0140-6736(20)31022-9
|
|
|
| [7] |
Spinner C D, Gottlieb R L, Criner G J, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA, 2020, 324(11):1048-1057.
doi: 10.1001/jama.2020.16349
|
|
|
| [8] |
Beigel J H, Tomashek K M, Dodd L E, et al. Remdesivir for the treatment of COVID-19-final report. New England Journal of Medicine, 2020, 383(19):1813-1826.
doi: 10.1056/NEJMoa2007764
|
|
|
| [9] |
Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochemical and Biophysical Research Communications, 2004, 323(1):264-268.
doi: 10.1016/j.bbrc.2004.08.085
|
|
|
| [10] |
Chang R, Sun W Z. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges. Drug Discovery Today, 2020, 25(10):1786-1792.
doi: 10.1016/j.drudis.2020.06.030
|
|
|
| [11] |
Gautret P, Lagier J C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 2020, 56(1):105949.
doi: 10.1016/j.ijantimicag.2020.105949
|
|
|
| [12] |
Huang M X, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. National Science Review, 2020, 7(9):1428-1436.
doi: 10.1093/nsr/nwaa113
|
|
|
| [13] |
Yu B, Li C Z, Chen P, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Science China Life Sciences, 2020, 63(10):1515-1521.
doi: 10.1007/s11427-020-1732-2
|
|
|
| [14] |
Yu B, Li C Z, Chen P, et al. Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs. Science China Life Sciences, 2021, 64(2):330-333.
doi: 10.1007/s11427-020-1782-1
|
|
|
| [15] |
Hoffmann M, Mösbauer K, Hofmann-Winkler H, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature, 2020, 585(7826):588-590.
doi: 10.1038/s41586-020-2575-3
pmid: 32698190
|
|
|
| [16] |
Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature, 2020, 585(7826):584-587.
doi: 10.1038/s41586-020-2558-4
pmid: 32698191
|
|
|
| [17] |
Cavalcanti A B, Zampieri F G, Rosa R G, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19. The New England Journal of Medicine, 2020, 383(21):2041-2052.
doi: 10.1056/NEJMoa2019014
|
|
|
| [18] |
Jin Z M, Du X Y, Xu Y C, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature, 2020, 582(7811):289-293.
doi: 10.1038/s41586-020-2223-y
|
|
|
| [19] |
Xiong R, Zhang L K, Li S L, et al. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein & Cell, 2020, 11(10):723-739.
|
|
|
| [20] |
Xu Y C, Jiang H L. Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase. Protein & Cell, 2020, 11(10):699-702.
|
|
|
| [21] |
Hu K, Wang M M, Zhao Y, et al. A small-scale medication of leflunomide as a treatment of COVID-19 in an open-label blank-controlled clinical trial. Virologica Sinica, 2020, 35(6):725-733.
doi: 10.1007/s12250-020-00258-7
|
|
|
| [22] |
Dai W H, Zhang B, Jiang X M, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science, 2020, 368(6497):1331-1335.
doi: 10.1126/science.abb4489
|
|
|
| [23] |
Yin W C, Mao C Y, Luan X D, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science, 2020, 368(6498):1499-1504.
|
|
|
| [24] |
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181(2): 271-280.e8.
doi: S0092-8674(20)30229-4
pmid: 32142651
|
|
|
| [25] |
Ju B, Zhang Q, Ge J W, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 2020, 584(7819):115-119.
doi: 10.1038/s41586-020-2380-z
|
|
|
| [26] |
Shi R, Shan C, Duan X M, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, 2020, 584(7819):120-124.
doi: 10.1038/s41586-020-2381-y
|
|
|
| [27] |
Cao Y L, Su B, Guo X H, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell, 2020, 182(1): 73-84.e16.
doi: 10.1016/j.cell.2020.05.025
|
|
|
| [28] |
Tang Y L, Wang Z H, Huo C Y, et al. Antiviral effects of Shuanghuanglian injection powder against influenza A virus H5N1 in vitro and in vivo. Microbial Pathogenesis, 2018, 121:318-324.
doi: 10.1016/j.micpath.2018.06.004
|
|
|
| [29] |
Su H X, Yao S, Zhao W F, et al. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacologica Sinica, 2020, 41(9):1167-1177.
doi: 10.1038/s41401-020-0483-6
|
|
|
| [30] |
Ni L, Zhou L, Zhou M, et al. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Frontiers of Medicine, 2020, 14(2):210-214.
doi: 10.1007/s11684-020-0757-x
|
|
|
| [31] |
Ni L, Wen Z, Hu X W, et al. Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial. Frontiers of Medicine, 2021, https://doi.org/10.1007/s11684-021-0853-6.
|
|
|
| [32] |
Ding Y W, Zeng L J, Li R F, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complementary and Alternative Medicine, 2017, 17(1):130.
doi: 10.1186/s12906-017-1585-7
|
|
|
| [33] |
Li R F, Hou Y L, Huang J C, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacological Research, 2020, 156:104761.
doi: 10.1016/j.phrs.2020.104761
|
|
|
| [34] |
Hu K, Guan W J, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine, 2021, 85:153242.
doi: 10.1016/j.phymed.2020.153242
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
